...有不少较弱势族群因经济因素而选择放弃治疗,不过,健保自6月起已针对大肠癌第四期转移的病患给付化学药物「抗癌妥(irinotecan)合并标靶药「癌思婷(bevacizumab)作为癌友的第一线治疗,估计可替病友每年省下至少8090万的医疗费用,大大减轻病患与家属的...
基于118个网页-相关网页
因为百时美施贵宝仍将拥有ImClone公司的抗癌拳头产品Erbitux(爱必妥)北美市场的销售收益,这将使收购方无法获得该公司现有的大部分收益。
Because BMS will keep the North American marketing rights for Erbitux, ImClone's blockbuster cancer drug, much of the firm's current revenue will not go to the buyer.
帕妥珠单抗目前仅用于试验,其实际上是一种单克隆抗体的抗癌成分。
Pertuzumab is approved only for experimental uses. It falls within a class of anticancer agents called monoclonal antibodies.
自从FDA在1997年批准了立普妥单抗,一些新的利用T细胞的能力靶向对抗癌细胞的策略也出现了。
Since the FDA approval of rituximab in 1997, several novel strategies that harness the ability of t cells to target cancer cells have emerged.
应用推荐